Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ

Cancer

Volumn 118, Issue 6, 2012, Pages 1515-1522

  Bayraktar, Soley ^a   Elsayegh, Nisreen ^a   Gutierrez Barrera, Angelica M ^a   Lin, Heather ^a   Kuerer, Henry ^a   Tasbas, Tunc ^b   Muse, Kimberly I ^a   Ready, Kaylene ^a   Litton, Jennifer ^a   Meric Bernstam, Funda ^a   Hortobagyi, Gabriel N ^a   Albarracin, Constance T ^a   Arun, Banu ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

BRCA 1 2 mutations; BRCAPRO; ductal carcinoma in situ; family history; predictive factors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GERM LINE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MATHEMATICAL MODEL; MUTATIONAL ANALYSIS; ONCOGENE; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SCORING SYSTEM; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS;

EID: 84857999736     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26428     Document Type: Article

References (26)

1. Li CI, Daling JR, Malone KE, et al. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1008-1011. (Pubitemid 40478573)
2. Erbas B, Provenzano E, Armes J, et al. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006; 97: 135-144.
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71. (Pubitemid 24345325)
4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378: 789-792. (Pubitemid 26004412)
5. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-689. (Pubitemid 28164626)
6. King MC, Marks JH, Mandell JB,. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643-646. (Pubitemid 37310920)
7. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006; 24: 863-871. (Pubitemid 46638837)
8. Sun CC, Lenoir G, Lynch H, et al. In-situ breast cancer and BRCA1. Lancet. 1996; 348: 408.
9. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998; 90: 1138-1145. (Pubitemid 28380718)
10. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997; 349: 1505-1510.
11. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20: 1480-1490. (Pubitemid 34260526)
12. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002; 20: 1260-1268. (Pubitemid 34177432)
13. Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer. 2003; 97: 1-11. (Pubitemid 36033857)
14. Claus EB, Petruzella S, Matloff E, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005; 293: 964-969. (Pubitemid 40271128)
15. Hwang ES, McLennan JL, Moore DH, et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007; 25: 642-647. (Pubitemid 350002918)
16. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003; 21: 41-45.
17. Arun B, Vogel KJ, Lopez A, et al. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res. 2009; 2: 122-127.
18. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003; 97: 1601-1608. (Pubitemid 36350702)
19. Hall MJ, Reid JE, Wenstrup RJ,. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. Cancer Prev Res. 2010; 3: 1579-1585.
20. Snedecor GW, Cochran WG,. Statistical Methods. 7th ed. Ames, IA: The Iowa State University Press; 1980.
21. Hosmer DW, Lemeshow S,. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons, Inc.; 2000.
22. Kaplan EL, Meier P,. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
23. Euhus DM, Smith KC, Robinson L, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002; 94: 844-851. (Pubitemid 34705056)
24. Smith KL, Adank M, Kauff N, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res. 2007; 13: 4306-4310. (Pubitemid 47105995)
25. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996; 56: 3663-3665. (Pubitemid 26272009)
26. Hartge P, Struewing JP, Wacholder S, et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999; 64: 963-970. (Pubitemid 30463027)